A2A
Computational solutions for life-threatening diseases
Operating in biopharma based in United States, A2A was founded in 2016.
Profile
A2A Pharmaceuticals has designed new drug candidates for cancers like Leukemia and other life threatening diseases. A2A’s technology platform optimizes the efficacy of such options while minimizing toxicity much faster and more precisely than competitors. We build and evaluate small molecule libraries that consist of thousands to millions of members until we obtain candidates with optimal properties and matches.
As a business in biopharma, A2A is listed here with the public details available about it.
The business is associated with United States.
Directory data places it at the SOSV portfolio company stage.
Recorded headcount: 11-50 employees.
Total disclosed funding stands at about $15K.
| Sector | Biopharma |
|---|---|
| Country | United States |
| Founded | 2016 |
| Employees | 11-50 |
| Stage | SOSV portfolio company |
| Total funding | $150,000 |
Website: a2apharma.com
Create a free account